The Medical Letter on Drugs and Therapeutics
Triptorelin (Triptodur) for Central Precocious Puberty
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an extended-release intramuscular suspension formulation of the gonadotropin-releasing hormone (GnRH) agonist triptorelin (Triptodur – Arbor/Debiopharm) for twice-yearly treatment of central precocious puberty (CPP) in children ≥2 years old. Triptorelin has been available in the US for years as Trelstar for palliative treatment of advanced prostate cancer. Before the approval of Triptodur, Trelstar was used off-label for treatment of CPP.

THE DISORDER – Central precocious puberty (also known as gonadotropin-dependent precocious puberty) is caused by early maturation of the hypothalamic-pituitary-gonadal (HPG) axis and defined by early-onset sexual development occurring before the age of 8 years in girls and 9 years in boys. It is more common in girls than in boys, affecting about 1 in 5,000-10,000 girls. Characteristics of CPP include early breast ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Triptorelin (Triptodur) for Central Precocious Puberty
Article code: 1537d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian